

TABLE 1 (Continued)

	All N=44	Hispanic N=21	Non-Hispanic Black N=15	Non-Hispanic White/Asian/Other N=8
Positive ^b	0 (0)	0 (0)	0 (0)	0 (0)
Testing declined ^b	2 (18)	0 (0)	2 (33)	0 (0)
N/A (diagnosed postpartum)	2	1	1	0
Postpartum care				
Infant separation ^b	9 (82)	4 (100)	4 (67)	1 (100)
Breastfeeding	2 (18)	4 (80)	4 (57)	1 (100)
Social determinants of health				
Housing insecurity	6 (14)	5 (24)	1 (7)	0 (0)

^aNon-severe = asymptomatic, mild, moderate.

^bDoes not include patients diagnosed postpartum.

These findings reflect the health consequences of the social, environmental, and structural effects of racism in the United States including differences in the prevalence of underlying chronic conditions and the disproportional impact of socioeconomic determinants of health. Of the non-Hispanic Black women with COVID-19, 67% had at least one of the following diagnoses: chronic lung disease, diabetes, hypertension, or obesity, which may have contributed to increased vulnerability to COVID-19. Almost one quarter of the Hispanic women with COVID-19 were experiencing housing insecurity. Ultimately, these preliminary data underscore the importance of collecting and reporting data based on race and ethnicity to better understand the impact of the pandemic in the United States and to further efforts to promote health equity.

AUTHOR CONTRIBUTIONS

Each author participated actively in drafting sections of the manuscript, editing, and approving the final, submitted version.

CONFLICTS OF INTEREST

The authors have no conflicts of interest.

REFERENCE

1. NIH. Management of Persons with COVID-19. <https://www.covid19treatmentguidelines.nih.gov/overview/management-of-covid-19/>. Accessed June 11, 2020.

Received: 19 June 2020 | Revised: 2 July 2020 | Accepted: 10 July 2020 | First published online: 8 September 2020

DOI: 10.1002/ijgo.13306

Obstetrics

Pre-gestational diabetes during the COVID-19 pandemic in Bergamo, Italy

Alessandro Roberto Dodesini^{1,*} | Silvia Galliani¹ | Elena Ciriello² | Rosalia Bellante¹ | Roberto Trevisan¹

¹Endocrinology and Diabetes Unit, ASST Papa Giovanni XXIII, Bergamo, Italy

²Gynecology and Obstetric Unit, ASST Papa Giovanni XXIII, Bergamo, Italy

*Correspondence

Alessandro Roberto Dodesini, Endocrinology and Diabetes Unit, ASST Papa Giovanni XXIII, 24127, Bergamo, Italy.

Email: adodesini@asst-pg23.it

KEYWORDS: Bergamo; COVID-19; Pre-gestational diabetes

The COVID-19 pandemic has caused the proliferation of a highly contagious and frequently fatal pneumonia around the world.¹ COVID-19 has severely affected Italy, and at the onset of this crisis, Bergamo, a city in northern Italy, regularly reported the highest number of cases in the country for many weeks. During outbreaks of infectious disease, pregnant women represent a high-risk population due to their increased susceptibility to infections, particularly when comorbidities such as pre-gestational diabetes (present in 0.5% of pregnant populations) are present.^{2,3}

Few data are available on pregnant women with pre-gestational diabetes during the COVID-19 pandemic.

From February 22 to May 17, 2020, all new-onset pregnant women with pre-gestational diabetes (nine with Type 1 [DMT1] and five with Type 2 diabetes) were screened for COVID-19 in the Diabetic and Pregnancy Clinic of Papa Giovanni XXIII Hospital in Bergamo. Their average age was 35 ± 5 years (mean \pm SD), BMI 29.1 ± 5.6 kg/m², A1c 43 ± 8 mmol/mol and diabetes duration 10 ± 8 years (with longer disease duration in DMT1 patients [$P = 0.05$]).

All patients used continuous glucose monitoring (CGM) for glucose control and telehealth was implemented in order to monitor glycemic trends at home.⁴

Retrospective observational studies not involving drugs do not require ethics committee approval and written informed consent in our institution.

Two pregnant women with DMT1 had a positive SARS-CoV-2 swab. One patient at 28 weeks of pregnancy with cough was hospitalized for COVID-19 pneumonia and was treated with hydroxychloroquine, antibiotic and antiviral therapy, and antithrombotic prophylaxis. A month later, the symptoms have regressed and the swab has returned negative for COVID-19. Mean daily glycemia, measured by CGM, was higher in both women when compared to that of women with negative COVID-19 swabs (134 ± 4 vs 108 ± 2 mg/dL, $P = 0.03$).

Although false negative tests are a possible risk factor, our screening procedure in all patients with pre-gestational diabetes during pregnancy revealed a prevalence of 14% for COVID-19, much less than that of the general population in the Bergamo area, estimated to be around 30–35% (unpublished data from Istituto Superiore di Sanità).

In spite of the small sample size, our results indicate that, after the onset of pregnancy, the combination of lockdown measures with the use of technology (especially CGM) and implementation of telehealth may have contributed to the relatively small number of pregnant women with pre-gestational diabetes who tested positive for COVID-19 in Bergamo, Italy. The observations of the present study could help colleagues in the management of pregnancy in women with pre-gestational diabetes during the COVID-19 pandemic.

AUTHOR CONTRIBUTIONS

ARD designed and coordinated the study, wrote, and revised the manuscript; SG, EC and RB enrolled patients and analyzed data; RT edited and revised the manuscript. All authors have contributed to and approved of the final version of the manuscript.

ACKNOWLEDGEMENTS

The authors acknowledge all of the women who participated in the study and the staff of the metabolic and obstetric units.

CONFLICTS OF INTEREST

The authors have no conflicts of interest.

REFERENCES

1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med*. 2020;382:727–733.
2. Shub A, Lappas M. Pregestational diabetes in pregnancy: complications, management, surveillance and mechanisms of disease – A review. *Prenat Diagn*. 2020; <https://doi.org/10.1002/pd.5718>. [Online ahead of print].
3. Yang Z, Wang M, Zhu Z, Liu Y. Coronavirus disease 2019 (COVID-19) and pregnancy: A systematic review. *J Matern Fetal Neonatal Med*. 2020;30:1–4.
4. Murphy H. Managing diabetes in pregnancy before, during and after COVID-19. *Diabetes Technol Ther*. 2020;22:454–461.